VION Biosciences Acquires Echelon Biosciences
August 22, 2024
VION Biosciences, the life-science platform backed by Iron Path Capital, has acquired Salt Lake City-based Echelon Biosciences, a specialist supplier of lipid-based excipients and lipid nanoparticles. The add-on strengthens VION's capabilities in lipid synthesis and lipid nanoparticle technology to support mRNA and gene-therapy development and advances the platform toward drug manufacturing while keeping Echelon’s leadership and operations intact.
- Buyers
- VION Biosciences, Iron Path Capital
- Targets
- Echelon Biosciences
- Sellers
- Bert V. Israelsen
- Platforms
- VION Biosciences
- Industry
- Biotechnology
- Location
- Utah, United States
- Transaction Type
- Addon
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.